Stroke Trial, Recruiting (NCT07344610)

Stroke Trial, Recruiting NCT07344610 Sponsor: General Hospital of Shenyang Military Region Condition: Stroke

Printed from Voxsanity (voxsanity.com.au) — NCT07344610 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Stroke

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with an ischemic stroke (a stroke caused by a blocked blood vessel) within the last 14 days, confirmed by a CT or MRI brain scan; or people who have imaging-confirmed narrowing of arteries in or around the brain of 50% or more
People who have been started on a high-dose cholesterol-lowering medication (such as atorvastatin 40–80 mg per day or rosuvastatin 20 mg per day) within 24 hours of being admitted to hospital, with a plan to continue this for at least one week
People who have signed a form giving their informed consent to participate

Who may not be able to join:

People who were already taking a cholesterol-lowering statin medication in the week before being admitted to hospital
People who are currently receiving other types of cholesterol-lowering treatments
People who have other serious health conditions (such as cancer or severe heart failure) where life expectancy is estimated to be less than one year
Women who are pregnant or breastfeeding
People who have taken part in another drug clinical trial within the past 3 months
People the trial investigator considers unsuitable for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07344610

Sponsor: General Hospital of Shenyang Military Region

Phase: Not Applicable

Status: Recruiting

Condition: Stroke

More information: https://clinicaltrials.gov/study/NCT07344610

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with an ischemic stroke (a stroke caused by a blocked blood vessel) within the last 14 days, confirmed by a CT or MRI brain scan; or people who have imaging-confirmed narrowing of arteries in or around the brain of 50% or more
People who have been started on a high-dose cholesterol-lowering medication (such as atorvastatin 40–80 mg per day or rosuvastatin 20 mg per day) within 24 hours of being admitted to hospital, with a plan to continue this for at least one week
People who have signed a form giving their informed consent to participate

Who may not be able to join:

People who were already taking a cholesterol-lowering statin medication in the week before being admitted to hospital
People who are currently receiving other types of cholesterol-lowering treatments
People who have other serious health conditions (such as cancer or severe heart failure) where life expectancy is estimated to be less than one year
Women who are pregnant or breastfeeding
People who have taken part in another drug clinical trial within the past 3 months
People the trial investigator considers unsuitable for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

General Hospital of Shenyang Military Region

Registry

ClinicalTrials.gov

Start date

8 January 2026

Est. completion

30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Absolute reduction in Low-Density Lipoprotein Cholesterol

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov